genes news from FierceBiotech
News
First miRNA drug enters human studies
Denmark's Santaris has kicked off a Phase I study of SPC3649, a potential treatment for hepatitis C infection. The trial marks the first time a microRNA drug has been tested in humans. SPC3649 will Read more...
SPOTLIGHT: Sangamo targets gene manipulation
Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a Read more...
Shares slip as developers see RNAi doubts
Shares of Opko and Alnylam have slid since a new study published in late March concluded that experimental drugs developed with the hot new science of RNA interference may work by activating the Read more...
Osmetech: biomarker license gives it diagnostics edge
Osmetech says its exclusive license for a key biomarker gives the company a big edge in identifying potential adverse reactions to Read more...
RNAi screening finds 273 proteins used by HIV
Harvard Medical School's Dr. Stephen J. Elledge and a team of scientists used RNA interference to screen thousands of protein-making genes, and have identified 273 proteins HIV needs in order to Read more...
Genizon pockets $31M CAD in fifth round
Canada's Genizon BioSciences has garnered $31 million Canadian in its fifth round of financing. The lead investor is BTF B.V. of Haarlem, The Netherlands, which specializes in late-stage biotech Read more...
More jaw-dropping scientific advances lay ahead
If the past year saw some incredible gains in biology, next year we should see even more sizeable advances. The sequencing of the human genome is now seven years old, but now we're witnessing new Read more...
Upstart biotech attracts A-list investors
An upstart biotech company focused on developing new therapies targeted at the genetic variations linked to dry age-related macular degeneration has raised $37 million in its first round. New Haven, Read more...
Nobel Prize goes to gene targeting trio
As a child, Mario Capecchi spent four years on the streets in his native Italy, surviving by stealing or begging for food. Today, he's one of three scientists--the other two are Oliver Smithies and Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets